It's been a long trip down the rabbit hole for Insmed Inc. to move ALIS (amikacin liposome inhalation suspension) before an FDA advisory committee. Briefing documents for Tuesday's meeting of the Antimicrobial Drugs Advisory Committee (AMDAC) suggest the drug, formerly known as Arikayce and Arikace, may receive a balanced review for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in adults as part of a combination antibacterial approach.